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Background: Fracture healing is a complex process regulated by a variety of cells and signalling molecules which
act both locally and systemically. The aim of this study was to investigate potential changes in patients’ mesenchymal
stem cells (MSCs) in the iliac crest (IC) bone marrow (BM) and in peripheral blood (PB) in relation to the severity of
trauma and to correlate them with systemic changes reflective of inflammatory and platelet responses following fracture.
Methods: ICBM samples were aspirated from two trauma groups: isolated trauma and polytrauma (n = 8 and 18,
respectively) at two time-points post-fracture and from non-trauma controls (n = 7). Matched PB was collected every
other day for a minimum of 14 days. BM MSCs were enumerated using colony forming-fibroblast (CFU-F) assay and
flow cytometry for the CD45-CD271+ phenotype.
Results: Regardless of the severity of trauma, no significant increase or decrease in BM MSCs was observed following
fracture and MSCs were not mobilised into PB. However, direct positive correlations were observed between changes
in the numbers of aspirated BM MSCs and time-matched changes in their serum PDGF-AA and -BB. In vitro, patients’
serum induced MSC proliferation in a manner reflecting changes in PDGFs. PDGF receptors CD140a and CD140b were
expressed on native CD45-CD271+ BM MSCs (average 12% and 64%, respectively) and changed over time in direct
relationship with platelets/PDGFs.
Conclusions: Platelet lysates and other platelet-derived products are used to expand MSCs ex vivo. This study
demonstrates that endogenous PDGFs can influence MSC responses in vivo. This indicates a highly dynamic,
rather than static, MSC nature in humans.
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Fracture healing is a highly co-ordinated physiological
process with initial haematoma formation followed by
an acute inflammatory response leading to an osteogenic
repair phase, all tightly regulated by a variety of cytokines
and other mediators and cells [1]. The systemic inflamma-
tory response associated with fracture can be indirectly
ascertained by elevation of C-reactive protein (CRP) and
total white cell counts as well as up-regulation in several
inflammation-related cytokines and chemokines [2-5].* Correspondence: pgiannoudi@aol.com
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unless otherwise stated.The later osteogenic phase is mediated locally via the
recruitment of mesenchymal stem cells (MSCs) from
adjacent periosteum, cortical bone and bone marrow [6].
Given the systemic nature of fracture repair, the ques-
tion arises whether MSCs at remote sites may undergo
changes in their local environment, even to the degree
that such MSCs may enter the systemic circulation. The
concept of systemic recruitment and homing of human
MSCs following fracture remains controversial but evi-
dence for this exists in rodent models [7,8]. In humans,
MSC-like cells have been reported in the peripheral
circulation of burn victims [9], following stroke [10]
or muscular damage [11] but not in any measurable
numbers in healthy controls [12,13]. Therefore, it isis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Tan et al. BMC Medicine  (2015) 13:6 Page 2 of 11possible that following fracture, and potentially in relation
to the severity of fracture, certain alterations in MSCs
at remote sites away from fracture, including alterations
in surface receptor expression or even more profound
changes sufficient to dislodge MSCs into the systemic
circulation, may occur.
Indeed several molecules associated with the systemic
inflammatory fracture repair response, such as platelet-
derived growth factors (PDGFs) [14], have been shown
to recruit MSCs by chemoattraction [15]. Fracture is
known to up-regulate the production of PDGF-BB [16]
and a positive effect of PDGF-BB on MSC proliferation
and migration in vitro is well-documented [14,17-19].
Therefore, we hypothesised that powerful signalling mol-
ecules, such as the PDGFs released into circulation after
fracture, may affect MSCs at sites remote to the initial
injury. To address this hypothesis we investigated MSCs
in the iliac crest (IC) bone marrow (BM) aspirates and
peripheral blood (PB) of patients suffering differing
severities of injury (fractures) and correlated MSC
changes with patient- and time-matched changes in
serum PDGFs as well as total white cell and platelet
counts. MSCs were enumerated using a classical colony-
forming assay-fibroblast (CFU-F) and flow cytometry for
the CD45-CD271+ phenotype [20-22].
Herein, we report numerical and receptor expression
changes in MSCs post-fracture in the IC BM, a site
remote from fracture that correlated with time-matched
changes in serum PDGFs. However, even the most severe
injury was not sufficient to mobilize MSCs into the PB.
These data provide the first evidence of the systemic
effect of endogenous platelet-derived growth factors on
the in vivo MSC pool in humans.Methods
Patient recruitment
Ethical approval was obtained for the study (reference
06/Q1206/127, Leeds (East) REC), with all patients
providing written informed consent. To address the
influence and role of differing severities of trauma on
MSC dynamics, patients were recruited into two groups
based on the severity of injury as defined by their Injury
Severity Score (ISS) [23]. Briefly, patients in the isolated
trauma group had ISS <16 and patients in the polytrauma
group had ISS ≥16. A third group of patients with no
acute trauma or injuries who were undergoing elective
orthopaedic surgery formed the control group. The demo-
graphics of the recruited patients are summarised in
Table 1. For MSC proliferation experiments using the
patient’s sera, cultured MSCs from four additional control
subjects (two male/two female, median age 31, range 21
to 35), characterised in our previous study [24], were
utilized.Sample collection
Patients recruited into both trauma groups had collec-
tion of IC BM as well as PB. IC BM aspiration could
only be carried out when the patient was undergoing
surgery, with the initial sampling occurring within
24 hours of injury (acting as baseline, day 0) and the
subsequent sampling, dictated by clinical need for a
further intervention, several days later (range 3 to
32 days). In addition, four patients had a third sampling
time point occurring over a year post-trauma (range
397 to 602 days), when they were admitted for elective
(non-acute trauma) operations.
For BM aspiration, consistency was assured in terms
of surgeon (same person for all patient samples), aspirate
location (anterior iliac crest, approximately 5 to 6 cm
posterior to the anterior superior iliac spine), tools (Stryker
306–111, 11-gauge, bevel tipped trocar, Kalamazoo, MI,
USA), volume of aspirate (20 ml) and draw method
(single draw to fill full 20 ml syringe [25]). The aspirate
was collected into an ethylenediaminetetraacetic acid
(EDTA)-containing tube (BD Vacutainer, Oxford, UK).
PB was collected every other day for 14 days and also
time-matched to each BM aspiration episode; samples
were taken into three tubes for different investigations,
with 20 ml collected in EDTA for the MSC enumer-
ation study, 20 ml taken in a clot accelerant tube (BD
Vacutainer, Oxford, UK) for serum isolation, and the
final sample (5 ml) sent to the hospital haematology
laboratory for processing of full blood count, including
platelet count and CRP.Sample processing and CFU-F assay
For MSC enumeration in both the IC BM aspirate and
PB, samples were initially processed for mononuclear
cell (MNC) isolation [20]. In brief, the sample was di-
luted 1:1 with phosphate buffered saline (PBS, Invitrogen,
Paisley UK), before being carefully layered onto Lympho-
prep (Axis-Shield, Dundee, UK) and subsequent centrifu-
gation at 650 g for 25 minutes. The MNC fraction was
washed twice in PBS and seeded into 10-cm diameter
dishes (Corning, Tewksbury, MA, USA) in 10 ml of MSC
culture media (NH Media, Milteny-Biotec, Bisley, UK), at
3 × 106 MNCs/dish, in triplicate, for the CFU-F assay. The
remaining MNCs were frozen down in freezing media and
stored in liquid nitrogen for flow cytometry investigations.
Expecting much lower MSC frequency in PB [12], PB
MNCs were seeded at a higher density (10 × 106 MNC/
dish). CFU-F cultures were maintained for two weeks and
CFU-F colonies scored, as described previously [26]. The
technical variation (between the three dishes) in colony
counts was approximately 23%. For all patients/data points,
the CFU-F data are presented as the number of CFU-F/ml,
calculated according to the formula:
Table 1 Patient demographics (total number =33)
Patient group Isolated trauma Polytrauma Controla
Number of patients n = 8 n = 18 n = 7
Sex 7 M/1 F 13 M/5 F 3 M/4 F
Median age (range) 39 (21 to 64) years 39 (21 to 54) years 40 (19 to 52) years
Median ISS (range) 6 (4 to 9) 27 (22 to 50)b n/a
Mechanism of injury 4 RTA, 4 fall from height 14 RTA, 3 fall from height, 1 assault n/a
Median follow-up period (range) 124 (22 to 160) weeks 105 (31 to 158) weeks n/a
aControl group were patients admitted electively for removal of metalwork; bP <0.05. F, female; ISS, injury severity score; M, male; RTA, road traffic accident.
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MSC enumeration using flow cytometry
Bone marrow MNCs were defrosted and the MSC fre-
quency was measured based on the CD45-CD271+ pheno-
type, as previously described [24], with some modifications.
Bone marrow MNCs were re-suspended at 1 x 107 cells/ml
in FACs buffer (PBS +0.5% bovine serum albumin
(BSA) +2 mM EDTA). Antibodies were added at the
manufacturers’ recommended concentrations and the
cells were incubated with the antibodies for 20 minutes.
Antibody combinations used were: CD45-PeCy7/CD271-
APC/CD140a-PE, CD45-PeCy7/CD271-APC/CD140b-PE
or an isotype controls combination (CD271-APC was
from Miltenyi Biotec, Bergisch Gladbach, Germany, all
other antibodies from BD Biosciences, Oxford, UK). The
cells were washed and re-suspended in FACs buffer con-
taining 100 ng/ml 4',6-diamidino-2-phenylindole (DAPI)
before analysing on a BD LSRII flow cytometer. Dead
cells were excluded from the analysis using DAPI before
gating on the CD45-CD271+ population and assessing the
expression of CD140a and CD140b (PDGF receptors α
and β, respectively) on these cells.
Cell counts and serum PDGF-AA and PDGF-BB
measurements in PB
The total white cell count, platelet counts and CRP mea-
surements were processed by the Leeds Teaching Hospitals
patient diagnostics laboratory. For investigations involving
patients’ sera, PB samples collected in clot accelerant
tubes were allowed to stand for 30 minutes at room
temperature (RT) prior to centrifugation for 15 minutes
at 2000 g. The serum was aliquoted (1 ml/tube) and frozen
at −80°C. The levels of two PDGF isoforms, −AA and –BB,
were measured using commercially available enzyme-linked
immunosorbent (ELISA) assay kits (Quantikine® ELISA
kits, R&D Systems, Abingdon UK).
Both MSC colony counts and PDGF levels were analysed
as the raw data (as CFU-F/ml or PDGF/ml), as well nor-
malized to day 0 (the latter indicative of increase/decrease
compared to the day 0 baseline, that is, <1 decrease, >1increase). The healthy control group recruited for PDGF
measurements (n =9) comprised five women and four men
who were non post-traumatic healthy volunteers, with me-
dian ages of 35 (range 19 to 63 years) and 35 (range 22 to
63 years), respectively, for the female and male groups.
MSC proliferation in response to patient’s serum
The effect of patient’s serum on MSC proliferation in vitro
was assessed in a colorimetric cell proliferation assay
based on a tetrazolium salt XTT (Roche, Welwyn Garden
City, UK), as described previously [27]. In brief, the assay
was performed using cultured MSCs from four donors, in
quadruplicate for each cell seeding density and each
serum sample. Cells were seeded at 125, 250 and 500
MSCs/well in 96-well plates and were allowed to attach
for 24 hours in (D)MEM/2% FCS (both from Invitrogen,
Paisley UK); the next day media were replaced with
150 μl of either non-haematopoietic (NH) media (positive
control wells), (D)MEM/10% FCS not optimized for MSC
growth (negative control wells) or (D)MEM/10% patient’s
serum (test wells). MSCs were allowed to grow and the
assay was stopped on day 5 by replacing the growth media
with the XTT labelling mixture; the colour change was
read at 450 and 620 nm using Opsys MR Plate reader
(Dynex Technologies, Worthing, UK). Optical densities
(ODs) were analysed separately for each seeding density
and MSC culture and normalised to the OD of the
positive control (NH media); the values for four MSC
cultures were next averaged for each seeding density
and serum proliferative indices (PIs <1 = less proliferative
than NH, >1 =more proliferative than NH) were recorded
for each time-point, for each serum.
Statistical analysis
As a Gaussian distribution could not be assumed due
to the sample size, non-parametric tests were carried out.
The Mann–Whitney test was used to compare differences
between two independent samples. The Wilcoxon signed-
rank test was carried out to compare differences between
paired samples. The Chi-square test was used for com-
parison of nominal data. Spearman’s rank correlation
coefficient was used to test the relationship between two
variables. A P-value of <0.05 was considered statistically
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carried out using IBM SPSS statistics 19 and all graphical
figures were made in Prism 6 (GraphPad Software, Inc.).
Results
MSC dynamics post fracture
In total, 33 subjects were recruited into this study (Table 1).
There were no statistically significant differences in the
age and gender distributions between the two trauma and
control groups. As expected, the differences in trauma
severity (ISS) between the isolated trauma and poly-
trauma groups were statistically significant (Table 1).
All patients had a sample (BM and PB) taken within
24 hours of injury (as baseline, Day 0) and a few days
later, coinciding with the time when the patients were
in the operating theatre for further surgical procedures
(Figure 1). Subsequently, the data were split into four
subgroups representing early response to fracture (1 to
3 days post injury), intermediate response (4 to 10 days),
late response (11 or more days) and return to baselineFigure 1 MSC dynamics in patients’ bone marrow (BM) and periphera
at different time-points post-injury (split into Subgroups: Early (Days 1 to 3 po
post injury) and Return to baseline (more than 1 year post injury). The solid lin
trauma patients; thick bars represent median values. B) Representative Da
demonstrating the abundance of CFU-Fs in the BM and their absence in PB. C(over 1 year). These time points were selected to repre-
sent the different phases of fracture healing [28].
Consistent with previous findings [22,29], large donor-
to-donor variation (up to 100-fold, from 10 to 1,000 CFU-
F/ml) was observed for both trauma groups (Figure 1A)
and in the control group (median 140 CFU-F/ml, range 33
to 265, n =7). Some trends for increased MSCs per
1 ml of BM aspirate were observed in Intermediate and
Late subgroups as well as in four patients studied long-
term (not significant). IC MSC numbers or responses were
not markedly different between the two injury severity
groups (Figure 1A, solid line – polytrauma, broken line –
isolated trauma).
Finally, there was no evidence for systemic mobilisation
of MSCs in any of the groups (Figure 1B). Since no gross
differences in MSC behaviours in isolated trauma and
polytrauma groups were found, all subsequent analysis
was performed on aggregated (pooled) data. Also BM
MSC changes after fracture were relatively subtle in
comparison with much larger donor-to-donor variation;l blood (PB) over time post injury. A) MSC changes in aspirated BM
st injury), Intermediate (days 4 to 10 post injury), Late (more than 11 days
e represents polytrauma patients and the broken line represents isolated
y 0 CFU-F dishes from patients from the corresponding subgroups,
FU-F, colony-forming unit – fibroblast; MSC, mesenchymal stem cell.
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data normalized to the ‘baseline’ (Day 0) values for each
individual patient.
Link between BM MSCs and serum levels of platelet-
derived growth factors
We next correlated individual changes in patients’ BM
MSCs with time-matched changes in their serum PDGF-
BB. As the role of PDGF-AA on MSC function is less-
known, we also measured PDGF-AA in patient’s serum
and correlated its changes after injury with that of MSCs
(Figure 2). In these experiments, we also investigated
individual changes in blood platelet counts in the same
patient, as both PDGF-AA and-BB are known to be pro-
duced by activated platelets [30] and platelet increases
have been described as a feature of the systemic inflamma-
tory response after trauma including fractures [3]. Total
white blood cells (WBCs) and CRP levels were addition-
ally used to evaluate the systemic inflammatory response
in these patients.
When both the cytokine levels and MSC levels were
normalised to Day 0 levels for each individual patient
(denoted as 100%), positive correlations were found
between changes in BM MSCs and changes in both
PDGF-AA and-BB (Figure 2A). The levels of both -AA
and -BB significantly correlated with that of platelets
(Figure 2B); no such correlations were found with WBC
counts (Figure 2C) or with CRP [see Additional file 1:
Figure S1]. This suggested that serum PDGF levels in
post-trauma patients were influenced by levels of circu-
lating platelets at that time rather than by a systemic
inflammatory response.
Similarly to previously published data on PDGF-BB
dynamics post-trauma [16], the levels of PDGF-AA showed
an overall initial decline following trauma, before rising by
an average of 1.7-fold by day 7 (Figure 2D). In approxi-
mately 20% of trauma patients, PDGF-BB and –AA levels
had risen above the normal physiological levels on day 7;
this was not the case for the control group, in which
PDGF-AA and –BB remained within the normal physio-
logical range [31] (median 4,128 pg/ml and 1,356 pg/ml,
ranges 2,482 to 5,261 and 623 to 1,996, respectively, n =9).
Similar to our BM MSC findings, no correlations were
observed between the levels of PDGF-AA or -BB and
ISS, or between isolated trauma and polytrauma groups
[see Additional file 2: Figure S2].
The observed parallel changes in serum PDGFs in
patients’ blood and the numbers of MSCs in their IC
BM post-injury suggested a potential systemic effect of
endogenous PDGFs on MSCs at the site distant to injury.
Patients’ sera induce MSC proliferation
To further explore the link between changes in serum
PDGFs and BM MSCs in the studied cohort of patients,we investigated whether patient’s serum had an effect
on MSC proliferation in a PDGF-dependent manner
(Figure 3). As expected, negative control medium produced
very low proliferation indices (PIs) of 0.74, 0.72 and 0.72,
for 125, 250 and 500 cells/well densities, respectively. Inter-
estingly, patient’s sera had more ‘proliferation-inducing
power’ than a positive control NH medium (PIs >1).
The data for the 125 cells/well density are shown in
Figure 3A. The other two seeding densities produced
very similar results (not shown).
We next compared the patterns of individual changes
in serum PIs with the corresponding changes in their
PDGF and platelet levels (Figure 3, B-D) and very similar
patterns of changes were found. In contrast, blood WCC
patterns of change were drastically different to serum PI
patterns (Figure 3E) emphasizing the specific contribution
of platelet-derived factors to serum proliferative power.
When the observed changes in serum PIs (for each patient)
were correlated with the corresponding changes in their
PDGF-AA, −BB or platelets, significant positive correla-
tions were found (Figure 3E and F).
Such trends were not observed when raw PDGF-
AA, −BB or raw platelet values were used, indicating
that, similar to our findings with BM MSCs, the observed
phenomena were patient-specific and that other serum
molecules were most likely involved in controlling MSC
proliferation. Because patients’ sera affected in vitro MSC
proliferation in a PDGF-dependent manner, we concluded
that a similar PDGF-driven effect on MSC proliferation
could take place in vivo, thus explaining the observed
increases in BM MSCs after injury in some patients.
Patient’s MSCs express PDGF receptors and modulate
their expression in response to changes in platelets
To investigate other potential changes in BM MSCs in
response to endogenous PDGFs, we investigated the
expression of PDGF receptors α and β (CD140a and
CD140b) on their surface [32] and analysed BM MSCs
based on their native CD45-CD271+ phenotype, as pre-
viously reported [21,22,24,32,33]. Figure 4 shows the
gating for MSCs and control haematopoietic lineage
cells (HLCs) and the expression of CD140a and CD140b
on both MSCs and HLCs from a representative trauma
patient (Day 0 baseline – top panel, Day 5 – bottom
panel).
Consistent with our previous findings [22], a significant
correlation between BM MSC numbers measured by the
CFU-F assay and by flow cytometry was evident (Figure 5A).
CD45-CD271+ MSCs, but not HLCs, showed abundant
PDGF receptors (Figure 5B). Interestingly, CD140a was
expressed at lower levels on MSCs than CD140b (average
12% and 64% positive cells, respectively), consistent with
previous studies on cultured MSCs [34] (Figure 5B). The
minimal presence of both PDGF receptors on HLC
Figure 2 Relationship between serum PDGF-AA and –BB and BM MSC numbers. A) Correlations between changes in serum PDGF-AA
or -BB with changes in BM MSCs in the same patient. Baseline (Day 0) data for each patient were denoted as 100% and the second time points
are shown as a proportionate fold-change. B) Correlations between serum PDGF-AA or -BB and circulating platelet levels in the same patient.
C) The lack of correlations between serum PDGF-AA or -BB with circulating white cell counts (WCC) in the same patients. D) Trends for PDGF-AA
changes over time, with initial decline after trauma followed by a gradual rise by day 7 post trauma. Left panel – raw data, right panel – data
normalised to baseline (Day 0 shown as 100%). BM, bone marrow; MSC, mesenchymal stem cell; PDGF, platelet-derived growth factor.
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erentially targeted MSCs rather than HLCs. In individual
patients, percentages of CD140a- or CD140b-positive
MSCs were not static and changed post-trauma showing
no similarities with each other (Figure 5C). When changes
in the percentages of CD140a- and CD140b-positive MSCs
were correlated with time-matched changes in patients’
blood (in the same patient), the strongest correlations were
observed with platelets themselves (Figure 5D).Discussion
In this study we investigated in vivo MSC responses at
sites remote from acute skeletal trauma and related these
to the systemic responses associated with fracture. We
observed no major changes in aspirated MSC numbers
following fracture; however, we were able to detect more
subtle, patient-specific changes that were related to time-
matched changes in the concentrations of PDGF–AA
and –BB in patients’ sera with these cytokines, in turn,
Figure 3 The effects of serum PDGF-AA and –BB on MSC proliferation. A) Proliferation indices (PIs), measured by xtt assay, of sera derived
from six patients at two time-points; adjacent bars represent Day 0 Baseline and the second time point; C represents negative control FCS, error
bars represent technical replicates. PIs were normalised to control NH media (PI =1). B) Platelet levels in PB of the same six patients taken at the
same two time-points. C) PDGF-AA and -BB levels in PB of the same six patients taken at the same two time-points. D) White cell levels in PB of
the same six patients taken at the same two time-points. Patterns in PI changes are similar to changes in PDGF-AA and -BB levels and platelet counts
but not WCC counts. E and F) Positive correlations between changes in sera PIs and changes in the corresponding levels of PDGF-AA, −BB and
platelets, in the same patient (<1 decline, >1 increase). MSC, mesenchymal stem cell; NH, non-haematopoietic; PB, peripheral blood; PDGF,
platelet-derived growth factor; WCC, white cell count.
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Figure 4 Enumeration of BM MSCs (left panels) and PDGFR
expression on MSCs (right panels) at the point of injury
(Day 0 baseline, A) and five days later (B). MSCs and control
haematopoietic lineage cells (HLCs) are identified as CD45-CD271+
and CD45 + CD271- cells, respectively. Right panels - the expression
of CD140a and CD140b on MSCs (empty histograms) and HLCs
(shaded histograms); flow cytometry plots from a representative
trauma patient are shown. BM, bone marrow; MSCs, mesenchymal
stem cells; PDGFR.platelet-derived growth factor receptor.
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in MSCs and PDGFs were mostly within the normal
physiological ranges indicating that the observed link
between MSCs and PDGFs may be a normal physio-
logical phenomenon rather than an injury-related one.
The expression of PDGF receptors CD140a and CD140b
on MSCs in vivo and the PDGF-depended effect of patient
serum on MSC proliferation in vitro confirmed the
biological plausibility of our observations. Conversely,
we did not observe MSC mobilisation into the blood,
even in the most severe trauma cases. Correspondingly,
over a follow up period of up to two years, none of the
patients were observed to develop any heterotopic
ossifications, indicative of MSC entrapment in tissues.
Systemic MSC release, their circulation and preferential
homing to the sites of fracture has been previously doc-
umented in animal models [12,35]. Our data show that
if this happens after skeletal injury in humans, the time
frame for such release must be exceptionally short-lived,
as circulating MSCs were not detectable in patients’ PB
within a few hours post-injury. It is, therefore, plausible
that any released MSCs could end up trapped in the lungs
[36]. This finding further highlights the existence ofpotentially critical differences in the MSC biology between
animal and human species [37].
To the best of our knowledge, only one previous study
described changes in BM MSC numbers in fracture pa-
tients; however, the timing post-trauma was not reported
[38] and no correlations with any systemic factors were
made. More recently, Marsell et al. showed an approxi-
mately 50% increase in CD73+ MSCs in the BM and
contralateral limbs of injured mice 7 to 14 days post
intramedullary injury; the authors linked the mobilisation
of MSCs to the systemic induction of bone morpho-
genetic protein 2 (BMP2} [39]. In our study, rather than
BMP2, we measured two platelet-derived growth factors –
PDGF-AA and -BB in patients’ sera, as well as their
corresponding receptors – CD140a and CD140b – on the
surface of CD45-CD271+ MSCs, from the same patient
and at the same time-matched point post-injury. We
chose PDGF-BB based on a large body of literature
indicating that PDGF-BB was a major cytokine respon-
sible for MSC proliferation [14,18,19,40,41]. PDGFB and
A genes have been also shown to be expressed locally at
healing sites between one to six weeks following injury
[42]. Additionally, PDGF-AA and its receptor CD140a
were selected because of recent publications indicating
CD140a-positivity of ‘true’ in vivo MSCs in a mouse
system [43,44].
To address a possible mechanism behind the systemic
effect on platelet-derived factors on patient’s BM MSCs
in vivo, we next investigated the effects of patients’ sera
on MSC proliferation in vitro. As expected, the serum
pairs with the highest rises in platelets (and PDGFs) had
the highest rises in their proliferative indices. Therefore,
it could be suggested that platelet-derived factors similarly
induced MSC proliferation in vivo. It is possible that
changes in platelet levels in our cohort of patients rep-
resented their bodies’ responses to the loss of platelets
due to bleeding/consumption, affecting their increased
production in order to reach normal physiological levels.
Such recovery of platelets (average platelet half-life of
100 hours [45]) and associated increases in PDGFs, could,
therefore, be responsible for parallel increases in MSCs in
some patients. MSCs responded to endogenous PDGF-
driven stimulation by changing the expression of PDGF
receptors CD140a and CD140b on their surface. Physio-
logical fluctuations in CD140a expression on the surface of
human MSCs may, therefore, limit its utility as a specific
MSC marker in humans [44].
Conclusions
Platelet lysates or autologous human serum rich in PDGFs
and other cytokines and chemokine molecules are currently
used for ex vivo MSC expansion [34,41,46]. Similarly,
platelet-rich plasma (PRP) is often used clinically to facili-
tate healing in tendons, cartilage and other skeletal tissues
Figure 5 PDGF receptor expression on BM MSCs, in relation to systemic changes, by flow cytometry. A) Positive correlation between BM
MSCs quantified by CFU-Fs assay and by flow cytometry for the CD45-CD271+ phenotype. B) Average proportions of PDGFRα(CD140a)- and
PDGFRβ(CD140b)-positive subpopulations within BM MSCs (empty bars) and control HLCs (dark bars), showing the abundance of both PDGF receptors
on MSCs compared to HLCs. Error bars represent SDs, n =10. C) CD140a (left panel) and CD140b (right panel) expression on CD45-CD271+ MSCs from
10 individual patients at two time-points; adjacent bars represent Day 0 Baseline and the second time point. D) Correlations between changes
in proportion CD140a and CD140b receptor positive MSCs with changes in platelet levels in the same patient (<1 decline, >1 increase). BM, bone
marrow; CFU-F, colony-forming unit-fibroblast; HLCs, haematopoietic lineage cells; MSCs, mesenchymal stem cells; PDGR, platelet-derived growth
factor; SD, standard deviation.
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dence that platelet-derived products could systemically
influence physiological MSC behaviours in humans and
that these MSC responses may be relatively fast. In this
respect, our data provide a biological explanation for
boosted MSC responses following PRP injections into
the iliac crest of human volunteers, documented recently
[50]. Because the observed correlations were valid in
respect to paired changes in platelets and PDGFs (that
is, for individual patients) and not for absolute values
of PDGF-AA or -BB/ml (that is, for the whole patient
cohort), our data also indicate that other systemic mod-
ulators are additionally involved in the systemic control
of the BM MSC pool in humans. With a further proteo-
mics study of patients’ sera, these other systemic factors
could be identified and potentially tested in the future
for their ability to ‘reactivate’ dormant MSCs lodged innon-healing tissues [51]. Therefore, we believe that our
study contributes to a better understanding of human
MSC biology in vivo and could potentially lead to the
development of novel ways of systemically targeting
endogenous MSCs in a variety of diseases.
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